| Species |
Human |
| Protein Construction |
LRP-5 (Glu644-Gln1263)_x000D_
Accession # O75197-1 |
mFc (IgG1) |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human Wnt SurrogateFc Fusion, hFc Tag at 5μg/ml (100μl/well) on the plate can bind LRP-5 mFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
96 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 100-115 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
A role for low-density lipoprotein-related receptor 5 (LRP5) in human bone was first established by the identification of genetic alterations that led to dramatic changes in bone mass. Shortly thereafter, mutations that altered the function of the sclerostin (SOST) gene were also associated with altered human bone mass. Subsequent studies of LRP5 and sclerostin have provided important insights into the mechanisms by which these proteins regulate skeletal homeostasis. |
| Synonyms |
LRP-5; LRP-7; LR3; BMND1; BMND1OPTA1; EVR1; EVR4; HBM; LR3VBCH2; LRP5; LRP7; OPPG; OPS; OPTA1; VBCH2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
